The impact of angiogenesis on the prognosis of advanced renal cell carcinomas

Acta Urologica Japonica

Volumn 50, Issue 3, 2004, Pages 157-163

  Kawata, Nozomu ^a   Yagasaki, Hiroki ^a   Hirakata, Hitoshi ^a   Nagane, Yusuke ^a   Morita, Koutaro ^a   Sugimoto, Shuji ^a   Igarashi, Takumi ^a   Takimoto, Yukie ^b  

^a SURUGADAI NIHON UNIVERSITY HOSPITAL   (Japan)

^b NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiogenic factor; Clinical response; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; ANGIOGENIC FACTOR; BLOOD CLOTTING FACTOR 8; GAMMA INTERFERON; THYMIDINE PHOSPHORYLASE;

ADULT; ADVANCED CANCER; AGED; ANGIOGENESIS; ARTICLE; CANCER SURVIVAL; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; NEPHRECTOMY; POSITIVE MEAN VASCULAR AREA; PROGNOSIS; RISK FACTOR;

AGED; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INTERFERON TYPE II; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOVASCULARIZATION, PATHOLOGIC; NEPHRECTOMY; PROGNOSIS; SURVIVAL RATE;

EID: 2442550842     PISSN: 00181994     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Health and welfare statistics association, Health and welfare statistics in Japan, pp 76-77. Tokyo, 1996
2. Guinan PD, Vogelzang NJ, Fremgen AM, et al.: Renal cell carcinoma: tumor size, stage and survival. J Urol 153: 901-903, 1995
3. Riese WE, Goldenberg K, Allhoff E, et al.: Metastatic renal cell carcinoma: spontaneous regression, long-term survival and late recurrence. Int Urol Nephrol 23: 13-25, 1991
4. Kawata N, Hirakata H, Yuge H, et al.: Cytoreductive surgery with liver-involved renal cell carcinoma. Int J Urol 7: 382-385, 2000
5. Usuki K, Saras J, Waltenberger J, et al.: Platelet-derived endothelial cell growth factor has thymidine phosphorylase activity. Biochem Biophy Res Commun 184: 1311-1316, 1992
6. Kawata N, Yagasaki H, Yuge H, et al.: Histopathologic analysis of angiogenic factors localized renal cell carcinoma: the influence of neadjuvant treatment. Int J Urol 8: 275-281, 2001
7. Japanese Urological association, The Japanese society of pathology, Japan radiological society, General rule for clinical and pathological studies on renal cell carcinoma. 3rd ed, pp 67-73, Kanehara. Tokyo, 1999
8. Kawata N, Takimoto Y, Hirakata H, et al.: Clinical trial of inhalant recombinant interferon-gamma in patients with pulumonary metastasis from renal tumor. Acta Urol Jpn 40: 773-776, 1994
9. Kawata N, Hirakata H, Igarashi T, et al.: A case study of metastatic renal cell carcinoma in lungs showing complete response to continuous subcutaneous injection of interferon α and γ. Acta Urol Jpn 42: 509-512, 1996
10. Kawata N, Ono M, Kodama M, et al.: A study of effective administration of interferon-γ in renal cell carcinoma regarding immunological influence of peripheral blood lymphocytes. Acta Urol Jpn 41: 21-26, 1995
11. Czarniecki CW, Fennie CW, Powers DB, et al.: Synergystic antiviral and anti proliferative activities of E coli derived human alfa and γ interferons. J Virol 49: 491-496, 1984
12. Aulitzky W, Gastl G, Aulitzky WE, et al.: Successful treatment of metastatic renal cell carcinoma with biological active dose of recombinant interferon-γ. J Clin Oncol 7: 1875-1884, 1989
13. Aulitzky WE, Aulitzky W, ellerhorst J, et al.: Intermittent low-dose IFN-γ treatment for metastatic renal cell carcinoma, analysis of factors predicting clinical response and long term survived. Onkologie 18: 339-345, 1995
14. Kawata N, Takimoto Y, Kodama M, et al.: Multivarariate analysis of clinicopathological factors and the efficacy of postoperative IFN-γ adjuvant therapy in 115 patients with renal cell carcinoma. Int J Clin Oncol 4: 164-169, 1999
15. Slaton JW, Inoue K, Perrotte P, et al.: Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced and pathological stage of renal cell carcinoma. Am J Pathol 158: 735-743, 2001
16. Nativ O, Sabo E, Reiss A, et al.: Clinical significance of tumor angiogenesis with localized renal cell carcinoma. Urology 51: 693-696, 1998
17. Suzuki K, Morita T, Hashimoto S, et al.: Thymidine phosphorylase/platelet-derived endothelial cell growth factor (PD-ECGF) associated with prognosis in renal cell carcinoma Urol Res 29: 7-12, 2001
18. Delahunt B, bethwaite PB and Thornton A: Prognostic significant of microscopic vascularity for clear cell carcinoma. Br J Urol 80: 401-404, 1997
19. Hofmockel M, Langer W, Theiss M, et al.: Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-α and 5-fluorouracil. J Urol 156: 18-21, 1996
20. Joffe JK, Banks RE, Forbes MA, et al.: A phase II study of interferon-α, interleukin-2 and 5-fluorouracil in advanced renal cell carcinoma: clinical data and laboratory evidence of protease activation. Br J Urol 77: 638-649, 1996
21. Morita T and Tokue A: Biomodulation of 5-fluorouracil by interferon-α in human renal carcinoma cells: relationship to the expression of thymidine phophorylase. Cancer Chemother Pharmacol 44: 91-96, 1999
22. Keane MP, Belperio JA, Arenberg DA, et al.: IFN-γ inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J Immunol 163: 5682-5692, 1999
23. Soejima K and Rollins BJ: A functional IFN-γ inducible protein-10/CXCL 10 specific receptor expressed by epithelial and endothelial cells that is neither CXCR3 nor Glycosaminoglycan. J Immunol 167: 6576-6582, 2001
24. Leek RD, Harris AL and Lewis CE: Cytokine networks in solid human tumors: regulation of angiogenesis. J Immunol 56: 423-435, 1994